尽管第三季度亏损，但 Dyne Therapeutics 的股价飙升，分析师维持正面评级。 Dyne Therapeutics' stock surged despite a Q3 loss, with analysts maintaining positive ratings.

Dyne治疗公司是一家研制基因肌肉疾病治疗办法的公司,在前一天关闭25.61美元之后,其股份在星期五上升到26.42美元。 Dyne Therapeutics, a company developing treatments for genetic muscle diseases, saw its shares rise to $26.42 on Friday after closing at $25.61 the previous day. 尽管第三季度每股亏损 0.96 美元，低于预期，但 Baird 和其他公司的分析师仍保持积极评级，目标价从 35 美元到 55 美元不等。 Despite a Q3 loss of $0.96 per share, missing estimates, analysts at Baird and others maintain positive ratings with price targets ranging from $35 to $55. 该公司的市场上限为26.1亿美元,公司内部人员最近出售股票。 The company has a market cap of $2.61 billion and insiders have recently sold shares.